Related Experiment Video

Updated: Jun 3, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

[Treatment of hepatitis C virus in HIV-positive patients]

Josep Mallolas Masferrer1, María Martínez-Rebollar, Montserrat Laguno Centeno

  • 1Servicio de Infecciones, Hospital Clínic-IDIBAPS, Barcelona, España. mallolas@clinic.ub.es

Gastroenterologia Y Hepatologia
|March 26, 2011
PubMed

Insights

Hepatitis C virus (HCV)-HIV coinfection is common, with current treatments yielding a 50% cure rate. Promising new antiviral therapies and genetic markers offer hope for improved outcomes in coinfected patients.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV)-HIV coinfection affects over 30% of HIV-positive individuals in Spain.
  • Current standard treatment for chronic HCV in HIV-positive patients is pegylated interferon plus ribavirin.
  • This combination therapy achieves a 50% cure rate, lower than in HCV monoinfection, with significant adverse effects leading to withdrawal in 10-20% of patients.

Purpose of the Study:

  • To review recent advancements and challenges in managing Hepatitis C virus (HCV) in the context of Human Immunodeficiency Virus (HIV) coinfection.
  • To highlight emerging trends including epidemic outbreaks, pharmacogenetic markers, and novel antiviral therapies.

Main Methods:

  • Review of current literature on HCV-HIV coinfection management.
  • Analysis of recent clinical trial data for new antiviral treatments.
  • Discussion of epidemiological trends and genetic factors influencing treatment response.

Main Results:

  • HCV-HIV coinfection presents unique challenges, including epidemic outbreaks of acute HCV among HIV-positive men.
  • Genetic polymorphisms near the IL28B gene are associated with treatment response and spontaneous HCV clearance.
  • New antiviral molecules are enabling triple combination therapies with promising high response rates in clinical trials.

Conclusions:

  • HCV-HIV coinfection management is evolving with new insights into genetic factors and treatment strategies.
  • Emerging epidemic outbreaks necessitate targeted prevention and intervention efforts.
  • Novel triple combination antiviral therapies show significant promise for improving cure rates in coinfected patients.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...